Deals and Financings   Nanjing Legend Biotech received a very large $350 million upfront payment from Janssen Biotech to partner Legend's impressively effective CAR-T candidate; Crown Bioscience, a CRO with facilities in China and elsewhere, will be acquired for $400 million by Japan 's JSR, double its previous valuation; JHL Biotech is planning a voluntary delisting from the Taiwan stock exchange; the $419 million biosimilar company operates in Taiwan and China ; China 's I-Mab Biopharma will pay up to $548 million for China rights to an immunology candidate developed by Genexine of South Korea; Ambrx signed a $143.5 million pact to in-license China rights for an anti-angiogenesis liver cancer treatment from Tracon Pharma; Huadong Medicine signed an $83 million agreement for China/Western Asia rights for a diabetes 2 treatment developed by vTv Therapeutics; Shanghai 's Zai Lab paid $44 million for China rights to a novel immunotherapy for gastric and gastro-esophageal tumors from Five Prime Therapeutics; Great Belief International Limited will pay $29 million to acquire SurgiBot, a minimally invasive surgical robot, from TransEnterix of North Carolina; Shanghai 's Yonghua Capital led a $25 million Series B funding in Taris Biomedical, a Boston company developing drug delivery devices; Jacobson Pharma made a $15 million investment in Shanghai Henlius Biotech and received Hong Kong rights to Henlius' Herceptin biosimilar;   Trials and Approvals CANbridge Life Sciences, a Beijing biopharma, filed an IND application in China for a Phase Ib/III trial of CAN017 in esophageal squamous cell cancer; Beijing 's BeiGene dosed the first patient in a China Phase II trial of its PARP inhibitor in patients with advanced ovarian cancer. Stock Symbols: (TPEX: 6554) (TPEx: 6540) (KOSDAQ: 095700) (NSDQ: TCON) (SZE: 000963) (NSDQ: VTVT) (NSDQ: ZLAB) (NYSE: TRXC) (HK: 2633) (NSDQ: BGNE) Share this with colleagues: // //